TopFunds

Johnson & Johnson

NYSE: JNJ

Stock price

255.56 USD

(+0%) TODAY

Drug Manufacturers - General
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
5.5
5.9
0.5
5.6
5.6
5.5
7.8
6.7
13.7
5.8
11
7.3%
02Free cash flow per share
5.6
5.6
6.5
6.8
7.4
7.6
7.4
6.5
7.1
8.2
8.1
3.7%
03Dividends per share
3
3.2
3.3
3.5
3.7
4
4.2
4.4
4.7
4.9
5.1
5.7%
04Dividends payout, %
53%
52.1%
6.9%
62.1%
65.6%
71.2%
52.8%
65.1%
33.5%
84.1%
46.2%
(1.4)%
PROFIT AND LOSS STATEMENT
05Revenue
70,074
71,890
76,450
81,581
82,059
82,584
78,740
79,990
85,159
88,821
94,193
3%
06% Change
-
-
-
-
-
-
-
-
-
-
-
3%
07Cost of revenue
(21,536)
(21,789)
(25,439)
(27,091)
(27,556)
(28,427)
(23,402)
(24,596)
(26,553)
(27,471)
(30,256)
3.5%
08Gross profit
48,538
50,101
51,011
54,490
54,503
54,157
55,338
55,394
58,606
61,350
63,937
2.8%
09% Margin
69.3%
69.7%
66.7%
66.8%
66.4%
65.6%
70.3%
69.3%
68.8%
69.1%
67.9%
68.2% A
10Operating expenses
(30,249)
(29,210)
(32,114)
(33,315)
(33,533)
(34,424)
(34,395)
(34,381)
(35,197)
(39,201)
(38,341)
2.4%
11% of Revenue
(43.2)%
(40.6)%
(42)%
(40.8)%
(40.9)%
(41.7)%
(43.7)%
(43)%
(41.3)%
(44.1)%
(40.7)%
(42)% A
12Operating Income
18,289
20,891
18,897
21,175
20,970
19,733
20,943
21,013
23,409
22,149
25,596
3.4%
13Income tax expense
(3,787)
(3,263)
(16,373)
(2,702)
(2,209)
(1,783)
(1,377)
(2,989)
(1,736)
(2,621)
(5,777)
4.3%
14Net Income
15,409
16,540
1,300
15,297
15,119
14,714
20,878
17,941
35,153
14,066
26,804
5.7%
15% Margin
22%
23%
1.7%
18.8%
18.4%
17.8%
26.5%
22.4%
41.3%
15.8%
28.5%
21.5% A
16Shares Outstanding
2,813
2,789
2,745
2,729
2,684
2,671
2,674
2,664
2,560
2,429
2,429
(1.5)%
17EPS Basic
5.6
6.1
0.5
5.8
5.7
5.6
7.9
6.8
13.9
5.8
11
7.1%
18EPS Diluted
5.5
5.9
0.5
5.6
5.6
5.5
7.8
6.7
13.7
5.8
11
7.3%
19EBITDA
23,494
24,283
24,249
25,933
24,655
23,929
26,751
26,605
23,320
24,781
41,055
5.7%
% Margin
33.5%
33.8%
31.7%
31.8%
30.1%
29%
34%
33.3%
27.4%
27.9%
43.6%
32.4% A
20Net Interest Income (expense)
(424)
(358)
(549)
(394)
39
(90)
(130)
214
489
577
85
-
21Net Debt / EBITDA
0.3
0.3
0.7
0.5
0.4
0.9
0.7
1
0.3
0.5
0.7
0.6 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
13,732
18,972
17,824
18,107
17,305
13,985
14,487
12,889
21,859
24,105
19,709
3.7%
23Short-term investments
24,644
22,935
472
1,580
1,982
11,200
17,121
9,392
1,068
417
393
(33.9)%
24Accounts receivable
10,734
11,699
13,490
14,098
14,481
13,576
18,984
16,915
14,873
18,927
17,178
4.8%
25Other current assets
3,047
3,282
2,537
3,649
2,486
3,132
-
5,830
4,514
-
4,153
3.2%
26Inventory
8,053
8,144
8,765
8,599
9,020
9,344
10,387
10,268
11,181
12,444
14,191
5.8%
27Total Current Assets
60,210
65,032
43,088
46,033
45,274
51,237
60,979
55,294
53,495
55,893
55,624
(0.8)%
Non-Current Assets
28Net property, plant & equipment
15,905
15,912
17,005
17,035
17,658
18,766
18,962
17,982
19,898
20,518
23,169
3.8%
29Long-term investments
-
-
-
-
-
-
-
-
-
-
-
-
30Other non-current assets
57,296
60,264
97,210
89,886
94,796
104,891
102,077
114,102
94,165
103,693
120,417
7.7%
31Total Non-Current Assets
73,201
76,176
114,215
106,921
112,454
123,657
121,039
132,084
114,063
124,211
143,586
7%
Total Assets
133,411
141,208
157,303
152,954
157,728
174,894
182,018
187,378
167,558
180,104
199,210
4.1%
LIABILITIES
Current Liabilities
32Accounts payable
6,668
6,918
7,310
7,537
8,544
9,505
11,055
9,889
9,632
10,311
11,991
6%
33Short-term debt
7,004
4,684
3,906
2,796
1,202
2,631
3,766
12,756
3,451
5,983
8,495
2%
34Other current liabilities
14,075
14,685
19,321
20,897
26,218
30,357
30,405
33,157
33,199
34,027
33,640
9.1%
35Total Current Liabilities
27,747
26,287
30,537
31,230
35,964
42,493
45,226
55,802
46,282
50,321
54,126
6.9%
Non-Current Liabilities
36Long-term debt
12,857
22,442
30,675
27,684
26,494
32,635
29,985
26,886
25,881
30,651
39,438
11.9%
37Other non-current liabilities
21,657
22,061
35,931
34,288
35,799
36,488
32,784
27,886
26,621
27,642
24,102
1.1%
38Total Non-Current Liabilities
34,514
44,503
66,606
61,972
62,293
69,123
62,769
54,772
52,502
58,293
63,540
6.3%
39Total Liabilities
62,261
70,790
97,143
93,202
98,257
111,616
107,995
110,574
98,784
108,614
117,666
6.6%
SHAREHOLDERS` EQUITY
40Common stock
3,120
3,120
3,120
3,120
3,120
3,120
3,120
3,120
3,120
3,120
3,120
-
41Retained earnings / (deficit)
103,879
110,551
101,793
106,216
110,659
113,890
123,060
128,345
153,843
155,791
168,978
5%
42Accumulated other comprehensive income / (loss)
(13,165)
(14,901)
(13,199)
(15,222)
(15,891)
(15,242)
(13,058)
(12,967)
(12,527)
(11,741)
(14,930)
1.3%
43Noncontrolling interests
-
-
-
-
-
-
-
-
-
-
-
-
44Total shareholders' equity
71,150
70,418
60,160
59,752
59,471
63,278
74,023
76,804
68,774
71,490
81,544
1.4%
45Total Liabilities and shareholders' Equity
133,411
141,208
157,303
152,954
157,728
174,894
182,018
187,378
167,558
180,104
199,210
4.1%
46Total Debt
19,861
27,126
34,581
30,480
27,696
35,266
33,751
39,642
29,332
36,634
47,933
9.2%
47Net Debt
6,129
8,154
16,757
12,373
10,391
21,281
19,264
26,753
7,473
12,529
28,224
16.5%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
15,409
16,540
1,300
15,297
15,119
14,714
20,878
17,941
35,153
14,066
26,804
5.7%
49Depreciation & amortization
3,746
3,754
5,642
6,929
7,009
7,231
7,390
6,970
7,486
7,339
7,503
7.2%
50Share-based compensation expense
874
878
962
978
977
1,005
1,135
1,138
1,162
1,176
1,354
4.5%
51Changes in working capital and other assets
(750)
(2,405)
13,152
(1,003)
311
586
(5,993)
(4,855)
(21,010)
1,685
(11,131)
31%
52Net cash flows from operating activities
19,279
18,767
21,056
22,201
23,416
23,536
23,410
21,194
22,791
24,266
24,530
2.4%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(3,463)
(3,226)
(3,279)
(3,670)
(3,498)
(3,347)
(3,652)
(4,009)
(4,543)
(4,424)
(4,832)
3.4%
54Purchases of investments / marketable securities
(40,828)
(33,950)
(6,153)
(5,626)
(3,920)
(21,089)
(30,394)
(32,384)
(10,906)
(1,726)
(920)
(31.6)%
55Proceeds from maturities of marketable securities
34,149
35,780
28,117
4,289
3,725
12,137
25,006
41,609
19,390
2,462
1,661
(26.1)%
56Other investing activities
2,407
(3,365)
(33,553)
1,840
(2,501)
(8,526)
357
(17,587)
(3,063)
(14,911)
(19,497)
-
57Net cash flows from investing activities
(7,735)
(4,761)
(14,868)
(3,167)
(6,194)
(20,825)
(8,683)
(12,371)
878
(18,599)
(23,588)
11.8%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
(5,290)
(8,979)
(6,358)
(5,868)
(6,746)
(3,221)
(3,456)
(6,035)
(813)
(2,432)
(5,953)
1.2%
59Dividends paid, net
(8,173)
(8,621)
(8,943)
(9,494)
(9,917)
(10,481)
(11,032)
(11,682)
(11,770)
(11,823)
(12,381)
4.2%
60Debt issuance (repayments), net
1,379
7,875
6,754
(3,949)
(2,881)
7,095
(990)
7,452
(2,734)
10,051
9,637
21.5%
61Other financing activities
1,238
1,174
874
801
1,529
487
1,431
1,394
(508)
1,072
3,158
9.8%
62Net cash flows from financing activities
(10,846)
(8,551)
(7,673)
(18,510)
(18,015)
(6,120)
(14,047)
(8,871)
(15,825)
(3,132)
(5,539)
(6.5)%
63Increase (decrease) in cash and cash equivalents
(791)
5,240
(1,148)
283
(802)
(3,320)
502
(360)
7,732
2,246
(4,396)
18.7%
64Cash and equivalents, ending balance
13,732
18,972
17,824
18,107
17,305
13,985
14,487
14,127
21,859
24,105
19,709
3.7%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
15,816
15,541
17,777
18,531
19,918
20,189
19,758
17,185
18,248
19,842
19,698
2.2%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
20252024202320222021201920182017

Johnson & Johnson (JNJ) financial statements and performance

Explore Johnson & Johnson (JNJ) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.